Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Google Secures Pentagon AI Deal for Classified Projects 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Standard Chartered Q1 Profit Hits Record on Wealth and Investment Banking Growth 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition 
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand 
VANCOUVER, British Columbia and DOYLESTOWN, Pa., Feb. 04, 2016 -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading therapeutic solutions company focused on developing a cure for chronic hepatitis B virus (HBV) infection, today announced that the company will be participating in two upcoming investor conferences.
- LEERINK Partners 5th Annual Global Healthcare Conferecne, February 11, 2016, New York
- RBC Capital Markets 2016 Global Healthcare Conference, February 23-24, 2016, New York
Arbutus’ President and CEO, Dr. Mark J. Murray, will present at the LEERINK conference on Thursday, February 11, 2016. A simultaneous webcast of the presentation can be accessed by visiting the Investor sections of www.arbutusbio.com and selecting Events and Presentations. Replays will be available on the Arbutus website following the event.
About Arbutus
Arbutus Biopharma Corporation is a biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic HBV infection. Our strategy is to target the three pillars necessary to develop a curative regimen for HBV: suppressing HBV replication within liver cells, stimulating and reactivating the body’s immune system so that it can mount an effective defense against the virus and, eliminating the reservoir of viral genomic material known as covalently closed circular DNA, or cccDNA that is the source of HBV persistence. Our portfolio of assets includes a broad pipeline of drug candidates for use in combination to develop a cure for HBV. To support continuous discovery of potential novel drug candidates and technologies, Arbutus has a research collaboration agreement with the Baruch S. Blumberg Institute that provides exclusive rights to in-license any intellectual property generated through the collaboration. The Baruch S. Blumberg Institute was established in 2003 by the Hepatitis B Foundation.
Arbutus is headquartered in Vancouver, BC, Canada with offices in Doylestown, PA, USA. For more information, visit www.arbutusbio.com.
Contact Information
Investors
Adam Cutler
Senior Vice President, Corporate Affairs
Phone: 604.419.3200
Email: [email protected]
Helia Baradarani
Manager, Investor Relations
Phone: 604.419.3200
Email: [email protected]
Media
Please direct all media inquiries to: [email protected]
